Roche says Ocrevus drug reduces need for walking aids for MS patients
October 13, 2021; 1:29 AM EDT
ZURICH, Oct 13 (Reuters) – Roche (ROG.S) said its Ocrevus treatment showed fewer patients with relapsing multiple sclerosis needed walking aids, the company said on Wednesday.
There was a 35% reduction in the need for a walking aid in patients with relapsing multiple sclerosis (MS) after seven and a half years of taking Ocrevus, the company said. There was also a 29% reduction in the 48-week progression in primary progressive MS after 8 years after starting taking the drug, it added.
Our Standards: The Thomson Reuters Trust Principles.